Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Success in Zero Based Budgeting comes from clear priorities and routine monitoring. Build consistency with simple benchmarks and alerts.
20,252 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Gas prices break above $4.50 per gallon nationwide as Middle East tensions surge, squeezing wallets ahead of peak dri...
A rare macro diamond pattern on XRP draws attention as traders weigh a potential long-range breakout. Analysts stress...
Bay Area housing shows a stark split: luxury homes surge on AI-era wealth, while affordable properties slip. Analysts...
Gold breaks above $4,770 as signs of de-escalation in global tensions ease inflation worries. Traders weigh safer hav...
Two popular ETFs both target consumer staples, but their weighting methods lead to distinct risk and return profiles....
Looking ahead to 2026, investors want a clear view of how Global Partners will navigate energy markets, margins, and ...
Britain pre-positions HMS Dragon in the Middle East as part of plans for a Europe-led mission to escort ships through...
Arm Holdings’ stock has jumped sharply this year on AI data center demand, yet a valuation gap and monetization hurdl...
Palantir has wowed investors with AI-enabled results, but its sky-high valuation raises questions. This guide uses hi...
Peloton has faced a brutal selloff, but the story isn’t finished. This article dives into whether Peloton is broken o...
Rising internal strife and political pressure push the FDA toward leadership change, with markets watching how the ag...